De novo drug design is one of the areas benefiting from DL. For example, DeepSARM is a deep learning extension of SARM for generative fragment-based analog design. DeepSARM introduces chemical novelty into the design process based on recent developments in generative modeling adaptation and the further development of chemical language models. Iterative DeepSARM (iDeepSARM) can rationally modify and extend sequence-to-sequence models and add iterative compound optimization and core-structure modifications.